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Abstract: 
Objective  
The use of antibiotic prophylaxis for prevention of infective endocarditis is 
controversial. In recent years, guidelines to cardiologists and dentists have 
advised restriction of antibiotic prophylaxis (AP) to high risk groups (in 
Europe and the USA), or against its use at all (in the UK). The objective of 
this systematic review was to appraise the evidence for use of AP for 
prevention of bacteraemia or infective endocarditis in patients undergoing 
dental procedures.  
 
Methods  
We conducted electronic searches in Medline, Embase, Cochrane Library 
and ISI Web of Science. We assessed the methodological characteristics of 
included studies using the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) criteria for observational studies, and 
the Cochrane Risk of Bias Tool for trials. Two reviewers independently 
determined the eligibility of studies, assessed the methodology of included 
studies and extracted the data.  
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Results  
We identified 178 eligible studies, of which 36 were included in the review. 
This included 10 time-trend studies, 5 observational studies and 21 trials. 
All trials identified used bacteraemia as an endpoint, rather than infective 
endocarditis. One time-trend study suggests that total AP restriction may 
be associated with a rising incidence of infective endocarditis, while data on 
the consequences of relative AP restriction are conflicting. Meta-analysis of 
trials indicates that AP is effective in reducing the incidence of bacteraemia 
(risk ratio 0.53, 95% CI 0.49-0.57, p < 0.01), but case control studies 
suggest this may not translate to a statistically significant protective effect 
against infective endocarditis in patients at low risk of disease.  
 
Conclusions  
The evidence base for the use of antibiotic prophylaxis is limited, 
heterogeneous and the methodological quality of many studies is poor. 
Post-procedural bacteraemia is not a good surrogate endpoint for infective 
endocarditis. Given the logistical challenges of a randomised trial, high 
quality case control studies would help to evaluate the role of dental 
procedures in causing infective endocarditis, and the efficacy of antibiotic 
prophylaxis in its prevention. 
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Abstract 
 
 
Objective 
The use of antibiotic prophylaxis for prevention of infective endocarditis is 
controversial. In recent years, guidelines to cardiologists and dentists have advised 
restriction of antibiotic prophylaxis (AP) to high risk groups (in Europe and the USA), 
or against its use at all (in the UK). The objective of this systematic review was to 
appraise the evidence for use of AP for prevention of bacteraemia or infective 
endocarditis in patients undergoing dental procedures. 
 
Methods  
We conducted electronic searches in Medline, Embase, Cochrane Library and ISI 
Web of Science. We assessed the methodological characteristics of included studies 
using the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) criteria for observational studies, and the Cochrane Risk of Bias Tool for 
trials. Two reviewers independently determined the eligibility of studies, assessed the 
methodology of included studies and extracted the data. 
 
Results  
We identified 178 eligible studies, of which 36 were included in the review. This 
included 10 time-trend studies, 5 observational studies and 21 trials. All trials 
identified used bacteraemia as an endpoint, rather than infective endocarditis. One 
time-trend study suggests that total AP restriction may be associated with a rising 
incidence of infective endocarditis, while data on the consequences of relative AP 
restriction are conflicting. Meta-analysis of trials indicates that AP is effective in 
reducing the incidence of bacteraemia (risk ratio 0.53, 95% CI 0.49-0.57, p < 0.01), 
but case control studies suggest this may not translate to a statistically significant 
protective effect against infective endocarditis in patients at low risk of disease. 
 
Conclusions  
The evidence base for the use of antibiotic prophylaxis is limited, heterogeneous and 
the methodological quality of many studies is poor. Post-procedural bacteraemia is 
not a good surrogate endpoint for infective endocarditis. Given the logistical 
challenges of a randomised trial, high quality case control studies would help to 
evaluate the role of dental procedures in causing infective endocarditis, and the 
efficacy of antibiotic prophylaxis in its prevention. 
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Abbreviations 
ACC/AHA - American College of Cardiology/American Heart Association  
AP – antibiotic prophylaxis 
ESC – European Society for Cardiology 
IE – infective endocarditis  
NICE – National Institute for Health and Care Excellence (UK) 
NVE – native valve infective endocarditis 
PVE – prosthetic valve infective endocarditis 
RCT – randomized controlled trial 
UK – United Kingdom  
USA – United States of America 
VGS – viridans group streptococci 
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Introduction 
 
 
Infective endocarditis is a rare but life-threatening disease.[1] Despite trends towards 
multidisciplinary ‘heart team’ care and early surgery, 1-year mortality approaches 
30%.[2] In patients with prosthetic heart valves, rheumatic and congenital heart 
disease, the risk of acquiring infective endocarditis is thought to be 10-50 fold higher 
than that of the general population.[3] Effective strategies for prevention of both 
community and healthcare-acquired infective endocarditis in at-risk groups are 
required.[4] 
 
The oral cavity was identified as a major portal of entry for bacteria in 1909 by 
Thomas Horder.[5] Oral streptococci are commensal flora of the oropharynx and 
account for 10-30% of cases of infective endocarditis, depending on the location, risk 
factor profile and socio-demographic characteristics of the population studied.[6, 7] 
Transient bacteraemia, which occurs in the setting of poor oral hygiene and 
periodontal diseases, dental procedures, or in the course of normal daily activities 
(e.g. tooth brushing), is thought to be a precursor to the development of some cases 
of infective endocarditis.[8]  
 
For over 50 years, oral antibiotic prophylaxis (AP) was given to patients at risk of 
infective endocarditis undergoing dental procedures. Between 2007 and 2009, 
however, the European Society for Cardiology (ESC), American Heart 
Association/American College of Cardiology (AHA/ACC) and the National Institute for 
Health and Care Excellence (NICE) recommended restriction of AP to varying 
degrees.[9, 10, 11] In Europe and the USA there was relative AP restriction to those 
at highest risk (e.g. patients with previous infective endocarditis, congenital heart 
disease and rheumatic heart disease, and selected heart transplant recipients) 
undergoing high-risk dental procedures. In the UK, NICE advised against use of 
prophylaxis entirely (total AP restriction) in 2008 but softened this stance in July 2016 
to state that antibiotics should not routinely be recommended as prophylaxis for 
dental procedures.[12] 
 
The rationale for relative or total AP restriction was threefold. First, as medicine 
shifted towards evidence-based practice there was (and remains) no randomised 
controlled trial assessing the efficacy of AP for prevention of infective endocarditis. 
Second, the relative importance of dental procedures as a cause of infective 
endocarditis remained in doubt, compared with other portals of entry or low grade 
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recurrent bacteraemia occurring in the course of daily life.[8, 13] Third, in moderate 
risk (and high risk in England) groups, the overall hazards of antibiotic use 
(particularly anaphylaxis and the development of antibiotic resistance) were felt to 
weigh against use of AP. The NICE guideline committee also deemed that AP was 
not cost effective as a result of lack of efficacy and the perceived risks of anaphylaxis. 
 
The primary object of this study was to provide a systematic review and synthesis of 
evidence that directly or indirectly informs clinical use of AP for at-risk patients 
undergoing dental procedures. The evidence base comprises three types of study: 
first, trials examining the effect of AP on the incidence of bacteraemia following 
dental procedures; second, observational studies assessing the efficacy of AP for 
prevention of infective endocarditis; and finally, time trend studies which examine the 
effect of changing national or international AP guidelines on the population incidence 
of infective endocarditis. 
 
 
  
Page 9 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Methods 
 
Eligibility and search strategy:  
We searched the following databases from inception until 25 February 2016 to 
identify studies of the efficacy of AP for the prevention of bacteraemia or infective 
endocarditis in patients undergoing dental procedures: Medline & Medline In-Process 
(OvidSP) [1946-present], Embase (OvidSP) [1974 to 2016 February 08], Cochrane 
Central Register of Controlled Trials (Cochrane Library, Wiley) [Issue 1 of 12, 
January 2016], Cochrane Database of Systematic Reviews (Cochrane Library, 
Wiley) [Issue 2 of 12, February 2016], Database of Abstracts of Reviews of Effects 
(Cochrane Library, Wiley) [Issue 2 of 4, April 2015], Science Citation Index Expanded 
& Conference Proceedings Citation Index- Science (Web of Science Core Collection) 
[1945-present], Clinicaltrials.gov (http://clinicaltrials.gov) and the WHO International 
Clinical Trials Registry Platform (http://apps.who.int/trialsearch/Default.aspx). Search 
terms used included subject headings and title/abstract keywords for bacterial 
endocarditis, antibiotics and prophylaxis (see search strategy in Appendix 1). We 
also searched the reference lists of all included articles. The following categories of 
study were excluded: studies conducted prior to 1960, studies of AP in patients 
undergoing cardiac surgery or implantation of cardiac electronic devices, topical 
therapies, and comparative antibiotic trials with no placebo/control arm. 
 
Data abstraction: 
We assessed methodological quality of studies using the Cochrane Risk of Bias 
tool[14] (for trials) or a checklist adapted from the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) criteria (for observational 
studies).[15] Two reviewers (TJC and JLH) independently adjudicated the eligibility of 
studies, assessed the methodology of included studies, and performed data 
extraction. Disagreement was resolved through consensus. 
 
We extracted data on the study design: for case control studies we extracted 
baseline characteristics on the cases and the controls; for time trend studies we 
extracted study population characteristics, the study time period, relevant guideline 
changes and effects on incidence of IE per 100,000 population. The primary outcome 
of interest was the incidence of infective endocarditis, incidence of (any) bacteraemia, 
or for time trend studies, population-adjusted incidence of infective endocarditis. 
Where total incidence of bacteraemia was not reported, the time point at which the 
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highest incidence of bacteraemia was observed in the placebo group was used for 
comparison. 
 
Data analysis: 
We derived summary tables to report methodological quality and main results of the 
included studies according to study design. For pooled effects we used a fixed-
effects model to generate Forest plots and used odds ratios as the summary 
measure. We assessed heterogeneity using I-square values, with 25%, 50% and 
75% representing mild, moderate and substantial heterogeneity, respectively.[16] 
Forest plots and data summary graphs were compiled using RevMan (Cochrane, 
UK) and SPSS (SPSS Inc., Chicago, IL, USA), respectively. 
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Results 
 
The electronic search identified 3830 articles, after removal of case reports, editorials, 
animal studies and duplicates (Figure 1). After screening of the title and/or abstract of 
these, 178 articles were deemed eligible for full text assessment. In total, 36 studies 
were deemed suitable for inclusion (see Supplementary Table 1 for excluded 
studies), comprising 10 time-trend studies, 5 observational studies (4 case-control 
studies and 1 retrospective cohort study) and 21 trials. All identified trials used 
bacteraemia as a surrogate endpoint for infective endocarditis. The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart for 
study inclusion is shown in Figure 1.  
 
Time trend population studies 
 
We identified 10 studies assessing the effect of changing national and international 
guidelines concerning the use of AP on the population incidence of infective 
endocarditis. These included 9 studies of relative AP restriction (from the USA and 
Europe) and 1 study examining the effect of total AP restriction (from the UK) (Table 
1). Changes in the guidelines between 2007 and 2009 by the ESC, ACC/AHA and 
NICE greatly reduced the use of antibiotic prophylaxis. Annual incidence was 
reported in two studies[17, 18] and obtained from the authors for two studies.[19, 20] 
Figure 2 shows the incidence of infective endocarditis per 100,000 population before 
and after changes in ACC/AHA and NICE guidelines. While only 1 study identified a 
significant rise in the incidence trend of infective endocarditis, it is important to note 
that this change was observed in the only population with total AP restriction. 
 
 
Observational studies 
 
We identified 5 observational studies for inclusion, including 4 case-control studies 
and 1 retrospective cohort study (Table 2). Data extracted included characteristics of 
cases and controls (or the two cohorts which were compared[21]), exposures and 
interventions (i.e. invasive procedures, use of AP), and, where possible, the numbers 
of patients specifically undergoing dental procedures (Table 2). All studies were 
assessed to be at high risk of intrinsic methodological bias (Supplementary Table 3). 
Meta-analysis was conducted on 3 studies with available data concerning the 
numbers of cardiac patients exposed to dental procedures, use of AP, and infective 
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endocarditis outcome. Overall, the odds ratio for use of AP in patients with infective 
endocarditis was 0.59 (95% confidence interval 0.27-1.30, p = 0.14, I2=48%), 
suggesting no statistically significant difference in exposure to AP between cases 
(patients with infective endocarditis) and controls. In Van Der Meer et al, cases and 
controls were analysed up to 30 days post-procedure and subgroups combined (first 
time and recurrent infective endocarditis; definite and possible indications for AP). If 
patients without a definite AP indication were excluded, this study provided an overall 
OR of 0.63 (95% CI 0.17-2.36) for AP, modifying the overall meta-analysis to an OR 
of 0.47 (95% CI 0.21-1.06, p = 0.07).  
 
 
Bacteraemia trials 
 
We included 21 studies investigating the effect of AP on the incidence of 
bacteraemia (as a surrogate for infective endocarditis) following a dental procedure. 
All studies reported the incidence of bacteraemia in a placebo group compared to an 
AP intervention group after a dental procedure. Some studies tested multiple 
antibiotic regimens (detailed in Supplementary Table 3), and some compared 
additional endpoints such as the duration or magnitude of bacteraemia, a breakdown 
of specific organisms grown, or antibiotic sensitivity patterns. A forest plot 
summarising a total of 35 antibiotic arms against control or placebo is shown in 
Figure 4. AP was associated with a risk ratio of 0.53 (95% CI 0.49-0.57, p < 0.01, I2 = 
90%) for bacteraemia in patients following dental procedures. 
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Table 1 – Time trend studies examining effect of antibiotic prophylaxis guideline change on the incidence of infective endocarditis  
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Bates 
2016[22] 27418041Paper USA 
Children ≤ 18 yrs identified 
from Pediatric Health 
Information System 
Database (29 hospitals) 
All cases – acute 
and subacute 
bacterial IE 2003 - 2014 
AHA/ACC  
April 2007 
Relative 
restriction No No NA 
Bikdeli 
2013[23] 23994421Paper USA Adults ≥ 65 yrs 
All cases - 
principal or 
secondary 
discharge dx of 
IE 1999-2010 
AHA/ACC  
April 2007 
Relative 
restriction No NA NA 
Dayer    
2015[19] 
& 
Thornhill 
2011[24]* 25467569Paper England, UK All  
All cases - 
primary dx acute 
or subacute IE 
January 1 2000 - 
March 31 2013 
NICE               
March 2008 
Total restriction Yes Yes Yes 
DeSimone 
2015[20] 
& 
De Simone 
2012[25]* 26141329Paper 
Olmsted County, 
Minnesota, USA Adults ≥ 18 yrs VGS IE 
January 1 1999 to 
December 31 
2013 
AHA/ACC          
April 2007 
Relative 
restriction No NA NA 
Duval     
2012[26] 22624837Paper 
3 regions of France 
(Greater Paris, 
Lorraine, and 
Rhône-Alpes) Adults ≥ 20 yrs 
All cases of IE 
and subgroups 
by causative 
organism 
3 survey years - 
1991, 1999, 2008 
French 
guideline 
restrictions         
2002 
Relative 
restriction No NA NA 
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Keller  
2016[27] 27816113 Paper Germany 
All patients hospitalizaed 
with acute or subacute IE 
IE due to 
Streptococcus 
and 
Staphylococcus 
(reported 
separately) 2005 - 2014 
ESC 
October 2009 
Relative 
restriction Yes Yes No 
Mackie 
2016[28] 26868840Paper 
Canada (except 
Quebec and the 
Northern 
Territories) 
All patients hospitalized 
with acute or subacute IE 
as main diagnosis 
All 
hospitalizations 
with primary dx of 
IE 
April 2002 - 
March 2013 
AHA/ACC          
April 2007 
Relative 
restriction 
Total IE increase, 
decrease in VGS Yes No 
Pant        
2015[17] 25975469Paper USA 
Patients in Nationwide 
Inpatient Sample with ICD 
codes for IE 
All cases of IE 
and subgroups 
by causative 
organism 2000 - 2011 
AHA/ACC          
April 2007 
Relative 
restriction Yes Yes Not performed 
Salam        
2014[29] NAAbstract Qatar 
All patients hospitalized 
with IE in State of Qatar All cases 2002 - 2012 
AHA/ACC          
April 2007 
Relative 
restriction No NA NA 
van den 
Brink 
2016[18] PendingPaper Netherlands 
All patients identified from 
the national healthcare 
insurance database All cases of IE 2005 - 2011 
ESC 
October 2009 
Relative 
restriction  
Yes, significant 
increase in VGS Yes NA 
  
* Earlier publications from same research group using same methodology. Study with longer follow-up used for analysis 
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Table 2 – Observational studies of antibiotic prophylaxis and infective endocarditis 
 
 
Study Study design Cases Controls Exposures and/or 
outcomes analysed 
Outcomes for patients 
undergoing dental 
interventions 
Included in meta-analysis? 
Horstkotte 
1987[21] 
Retrospective 
cohort study 
Group 1: 229 patients 
with prosthetic heart 
valves, in whom 287 
diagnostic/therapeutic 
procedures were 
performed using a 
prophylactic antibiotic 
regime   
 
Group 2: 304 patients with 
prosthetic heart valves, who had 
undergone “one of the 
procedures we regard as 
requiring endocarditis 
prophylaxis, without having 
received any antibiotic regime” 
Incidence of PVE Subgroup analysis of 
patients undergoing dental 
procedures: 2 cases of PVE 
from 117 patients 
undergoing dental 
procedures without AP. 0 
cases (total number of 
patients undergoing dental 
procedures is not reported) 
in those with AP 
No – as no denominator 
provided for total number of 
dental procedures in the group 
which received AP 
Imperiale 
1990[30] 
Case control Patients with a first 
episode of NVE within 
12 weeks of a dental 
procedure 
Patients matched for age, high-
risk lesion on echo and 
frequency of dental visit 
Use of antibiotics pre 
and after procedure 
AP used in 1/8 cases, 15/24 
controls 
Yes 
Lacassin 
1995[31] 
Case control Adults with definite, 
probable or possible 
IE. PVE < 1 year from 
implantation excluded 
Subjects without IE recruited 
from wards/echocardiography 
during same period as cases. 
Matched 1:1 for sex, age, group 
of underlying cardiac condition 
All invasive procedures 
(not limited to dental) 
in 3 month period prior 
to IE, and use of AP 
Subgroup analysis of 
patients undergoing dental 
procedures with cardiac 
disease: AP used in 6/26 
cases, 6/22 controls  
Yes – only patients undergoing 
dental procedures 
Strom 
1998[32] 
Case control Persons with 
community-acquired IE 
not associated with IV 
drug use 
(39 prosthetic valve) 
104/273 cases had 
cardiac disease 
Community residents, matched 
by age, sex, and neighbourhood 
of residence – i.e. not matched 
by cardiac risk factors 
17/283 had cardiac disease 
Survey on risk factors 
including recent dental 
treatment, use of AP 
Only the patients with 
cardiac risk factors are 
relevant 
Study does not state what 
proportion of this subgroup 
received AP 
No – details not provided for 
number of controls with cardiac 
disease given antibiotic 
prophylaxis – without this 
cannot be compared to the 
cases 
Van der Meer 
1992[33] 
Case control Patients with NVE and 
cardiac risk factors and 
<180 days post 
procedure (medical or 
dental) requiring 
prophylaxis 
Cardiac outpatients matched for 
age and procedures 
Survey of recent dental 
procedures and use of 
AP 
Caveat is that not all 
interventions have 
‘definite’ indication for 
AP 
30-day rate of IE analysed 
for cases 
Equivalent time period used 
for controls follow-up (Table 
3) 
AP used in 5/25 cases, 8/42 
controls 
Yes, although not possible to 
separate out the number of 
patients who underwent dental 
procedures (cf. other medical 
procedures) although these 
account for <10% of both 
cases and controls 
 
Abbreviations: AP – antibiotic prophylaxis, IE – infective endocarditis, NVE – native valve endocarditis, PVE – prosthetic valve endocarditis 
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Discussion 
 
In this study we have systematically reviewed the evidence base for the use of AP for 
prevention of infective endocarditis. This comprises a) population time trend analyses 
of the effect of changing national and international guidelines on the incidence of 
infective endocarditis b) focused observational studies, including 4 case control 
studies and a retrospective cohort, and c) trials of antibiotics after dental procedures, 
using bacteraemia as a surrogate endpoint for the development of infective 
endocarditis. No randomised controlled trial (RCT) of AP has been undertaken.  
 
This is the first study to systematically appraise the total evidence base for AP across 
a range of study designs. We have conducted a comprehensive search and 
extensively reviewed studies that either directly or indirectly address the question of 
AP efficacy. All studies have been quality assessed, with risk of bias assessed in a 
systematic manner. However, our study has some limitations. Our conclusions are 
limited by the poor methodological quality of included studies (and their 
heterogeneity) and the lack of randomized trials. Furthermore, we have excluded 
studies prior to 1960 (in order to maintain relevance to current antimicrobial practice) 
and have not reviewed the data on use of AP to prevent infective endocarditis in 
animal models, where some evidence suggests that single dose amoxicillin 
prophylaxis is effective in preventing streptococcal infective endocarditis. 
 
In total, we identified 10 studies assessing the effect of national and international 
guideline change on the incidence of infective endocarditis. In all countries where AP 
is still recommended, there has been no significant change in the overall rate of 
increase of IE, although in several it is claimed that there has been an increase in the 
number of streptococcal cases. However, IE rates have increased overall in the only 
study of total AP cessation from the UK.[19] Although this study was unable to 
ascertain whether this increase was driven by a rising incidence of streptococcal 
infective endocarditis, a further study is underway to identify the microbiological 
aetiology of these additional cases. These studies are intrinsically at high risk of 
methodological bias (as determined by the STROBE criteria) due to their 
observational study design and cannot fully account for confounding variables. 
Studies relying solely on discharge coding may not adequately account for re-
admissions or re-coding of historical diagnoses. Pant et al included secondary 
diagnoses of infective endocarditis in their analysis, leading to higher estimates than 
other studies.[17] Several smaller population studies with validated diagnoses have 
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provided lower estimates for the incidence of infective endocarditis of fewer than 5 
cases per 100,000 per year.[7, 34, 35] Finally, even the larger time trend studies may 
remain underpowered to detect a significant change in infective endocarditis 
incidence given the limited duration of follow-up. In particular, detection of any small 
change in incidence in studies of relative AP restriction requires a large population or 
prolonged duration of follow-up.  
 
We identified 5 observational studies assessing the efficacy of AP. These were 
retrospective, of poor methodological quality, varying design (4 case control, 1 
retrospective cohort) and small sample size. Accordingly, they are at high risk of 
methodological bias and conclusions should be drawn with caution. With this major 
caveat, our meta-analysis of 3 observational studies did not show a statistically 
significant difference in exposure to AP in cases (patients with infective endocarditis 
after dental procedures) compared to controls. There was a trend towards a 
protective effect of AP, however, and the lack of statistical significance may reflect 
the small sample sizes in the primary studies. Furthermore, most of the patients in 
these studies did not have replacement valves or other high-risk pathology so would 
not have been considered for AP even according to US or European guidelines.  Two 
studies (Duval; Horstkotte) not included in our meta-analysis examined the protective 
effect of AP in patients with replacement valves. Both suggested a protective effect 
from AP. In the study by Horskotte et al, 229 patients with replacement heart valves 
were followed after 287 diagnostic interventions (including some dental) requiring 
AP.[21] A group of 304 patients who had undergone invasive procedures without AP 
was used for comparison. Six cases of infective endocarditis occurred in the group 
with no AP, compared to 0 in the AP group. In a population study by Duval et al, 
approximately 14 times more IE occurred after unprotected than protected dental 
procedures in people with replacement valves.[36] The study by Horstkotte et al was 
excluded because the number of dental procedures was not stated and the study by 
Duval et al was excluded due to use of extrapolated rather than absolute numbers.  
 
We identified 21 trials assessing the efficacy of AP in reducing the incidence of 
bacteraemia after dental procedures. Overall, AP is effective at reducing the 
incidence of bacteraemia. Other surrogate measures addressed in some studies 
include the nature of isolated bacteria, the duration of bacteraemia, and its 
magnitude. However, the relationship between bacteraemia and infective 
endocarditis is not straightforward. In particular, the relative importance of 
bacteraemia following dental extraction remains debated, and low level bacteraemia 
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occurs commonly in association with daily activities such as tooth brushing, 
especially in the setting of periodontal disease.[37] As such, its validity as a 
surrogate endpoint for infective endocarditis is uncertain.  
 
An RCT of AP has been debated for several decades but is unlikely to be performed 
for several reasons. Using infective endocarditis as the primary outcome, such a trial 
would require several hundred thousand participants with a prolonged duration of 
recruitment and follow-up. In addition, there may be a lack of equipoise in an RCT, 
given that the standard of care for high-risk individuals (based on ESC and ACC/AHA 
guidelines) is to give AP. The size, scale and cost of a government-sponsored trial 
has been deemed unacceptable to national funding bodies in both the UK and 
USA.[38]  
 
There is general acceptance that the majority of cases of infective endocarditis 
caused by oral bacterial species are likely to result from frequent bacteraemia arising 
from routine daily activities, but this does not exclude the possibility that some cases 
result from infrequent invasive dental procedures.[13] The focus of clinical research 
on IE prevention has therefore shifted in recent years from surrogate bacteraemia 
studies to those examining the role played by inflammation and ulceration of gingival 
tissues. A large multicentre case control study assessing the associations between 
poor oral hygiene, dental disease and infective endocarditis is currently underway 
and may provide the necessary data to permanently shift the focus away from AP as 
the best strategy to prevent IE.  
 
As the debate continues, infective endocarditis is changing. Oral streptococci – the 
target of AP – account for a falling proportion of cases in developed world series.[7] 
In the absence of high quality evidence and with significant barriers to an RCT, 
uncertainty is likely to prevail. For cardiologists and dental practitioners faced with 
high-risk individuals, AP remains a low risk, inexpensive approach that may have 
benefit.[39, 40] We have previously described a framework for discussion of the 
risk:benefit balance for high-risk patient groups based on current ESC guidelines.[41] 
Despite the low quality and limited evidence base, these guidelines (and their 
counterpart from the ACC/AHA) advising AP for patients at highest risk provide a 
pragmatic and justified approach.  
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Figure Legends 
 
 
Figure 1. PRISMA flow chart 
 
Figure 2. Annual incidence of infective endocarditis reported in time-trend 
analyses. The data for annual incidence or prevalence was reported in three 
studies[17, 18, 27] and obtained from the authors for two studies.[19, 20] The 
incidence of viridans streptococal infective endocarditis in DeSimone et al was 0 in 
2009 and 2011. The incidence values for Pant et al [17] are higher than other studies 
due to the inclusion of infective endocarditis as both a primary and secondary 
diagnosis (included solely as a primary diagnosis in the other studies). 
 
Figure 3. Meta-analysis of case-control studies testing the association between 
antibiotic prophylaxis (AP) and infective endocarditis after dental procedures. 
In these studies, cases are patients with infective endocarditis and controls are 
matched patients at risk (Table 2). The number of ‘events’ is the use of AP in each 
group as a proportion of the total number of procedures. Overall, the odds ratio of AP 
comparing patients with infective endocarditis to those without is 0.59 (95% 
confidence interval 0.27-1.30, p = 0.14), suggesting no statistically significant 
difference in AP exposure between cases and controls. Abbreviations: AP antibiotic 
prophylaxis; IE infective endocarditis. 
 
Figure 4. Meta-analysis of trials of antibiotic prophylaxis for prevention of 
bacteraemia after dental procedures. Where an individual study tested multiple 
antibiotic regimes, these are represented as (a), (b) etc. and compared against the 
control/placebo arm. Details of the dental procedure and antibiotic regimen are 
shown in Supplementary Table 5. Overall, use of AP was associated with a risk ratio 
for bacteraemia of 0.53 (95% CI 0.49-0.57, p < 0.01, I2 = 90%). Abbreviations: AP 
antibiotic prophylaxis 
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Figure 1. PRISMA flow chart  
Figure 1  
155x154mm (300 x 300 DPI)  
 
 
Page 25 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Figure 2. Annual incidence of infective endocarditis reported in time-trend analyses. The data for annual 
incidence or prevalence was reported in three studies[17, 18, 27] and obtained from the authors for two 
studies.[19, 20] The incidence of viridans streptococal infective endocarditis in DeSimone et al was 0 in 
2009 and 2011. The incidence values for Pant et al [17] are higher than other studies due to the inclusion of 
infective endocarditis as both a primary and secondary diagnosis (included solely as a primary diagnosis in 
the other studies).  
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31x19mm (600 x 600 DPI)  
 
 
Page 26 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Figure 3. Meta-analysis of case-control studies testing the association between antibiotic prophylaxis (AP) 
and infective endocarditis after dental procedures. In these studies, cases are patients with infective 
endocarditis and controls are matched patients at risk (Table 2). The number of ‘events’ is the use of AP in 
each group as a proportion of the total number of procedures. Overall, the odds ratio of AP comparing 
patients with infective endocarditis to those without is 0.59 (95% confidence interval 0.27-1.30, p = 0.14), 
suggesting no statistically significant difference in AP exposure between cases and controls. Abbreviations: 
AP antibiotic prophylaxis; IE infective endocarditis.  
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Figure 4. Meta-analysis of trials of antibiotic prophylaxis for prevention of bacteraemia after dental 
procedures. Where an individual study tested multiple antibiotic regimes, these are represented as (a), (b) 
etc. and compared against the control/placebo arm. Details of the dental procedure and antibiotic regimen 
are shown in Supplementary Table 5. Overall, use of AP was associated with a risk ratio for bacteraemia of 
0.53 (95% CI 0.49-0.57, p < 0.01, I2 = 90%). Abbreviations: AP antibiotic prophylaxis  
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SUPPLEMENTARY DATA 
 
 
Supplementary Appendix 1: Search strategy 
 
 
 
MEDLINE 
 
 
# ▲ Searches 
1 exp Endocarditis, Bacterial/ or Endocarditis/ 
2 ((bacter* or infective or inflammatory) adj5 endocarditis).ti,ab. 
3 ((infect* or inflam*) adj5 endocardium).ti,ab. 
4 endocarditis.ti. 
5 1 or 2 or 3 or 4 
6 exp Anti-Bacterial Agents/ 
7 (antibiotic? or anti-biotic? or antimicrobial? or anti-microbial? or antibacterial? or anti-bacterial? or anti-infective).ti,ab. 
8 (penicillin or amoxicillin or ampicillin or cefazolin or ceftriaxone or cephalexin or clindamycin or azithromycin or clarithromycin or vancomycin).ti,ab. 
9 6 or 7 or 8 
10 (prophyla* or prevent* or premedicat* or pre-medicat*).ti,ab. 
11 9 and 10 
12 Antibiotic Prophylaxis/ 
13 11 or 12 
14 5 and 13 
15 exp Endocarditis, Bacterial/pc [Prevention & Control] 
16 9 and 15 
17 (endocarditis and prophyla*).ti. 
18 14 or 16 or 17 
19 exp animals/ not humans.sh. 
20 18 not 19 
 
EMBASE 
 
 
# ▲ Searches 
1 exp endocarditis/ 
2 ((bacter* or infective or inflammatory) adj5 endocarditis).ti,ab. 
3 ((infect* or inflam*) adj5 endocardium).ti,ab. 
4 endocarditis.ti. 
5 1 or 2 or 3 or 4 
6 exp *antibiotic agent/ 
7 (antibiotic? or anti-biotic? or antimicrobial? or anti-microbial? or antibacterial? or anti-bacterial? or anti-infective).ti,ab. 
8 (penicillin or amoxicillin or ampicillin or cefazolin or ceftriaxone or cephalexin or clindamycin or azithromycin or clarithromycin or vancomycin).ti,ab. 
9 6 or 7 or 8 
10 (prophyla* or prevent* or premedicat* or pre-medicat*).ti,ab. 
11 9 and 10 
12 Antibiotic Prophylaxis/ 
13 11 or 12 
14 5 and 13 
15 (endocarditis and prophyla*).ti. 
16 14 or 15 
17 (exp animals/ or nonhuman/) not human/ 
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18 16 not 17 
 
 
COCHRANE 
 
ID Search 
#1 endocarditis:ti,ab,kw  (Word variations have been searched) 
#2 ((bacter* or infective or inflammatory) near endocarditis):ti,ab,kw  (Word variations have been searched) 
#3 abe or sabe:ti,ab,kw  (Word variations have been searched) 
#4 #1 or #2 or #3  
#5 MeSH descriptor: [Anti-Bacterial Agents] explode all trees 
#6 (antibiotic? or anti-biotic? or antimicrobial? or anti-microbial? or antibacterial? or anti-bacterial? or anti-infective):ti,ab,kw  (Word variations have been searched) 
#7 penicillin or amoxicillin or ampicillin or cefazolin or ceftriaxone or cephalexin or clindamycin or azithromycin or clarithromycin or vancomycin:ti,ab,kw   
(Word variations have been searched) 
#8 #5 or #6 or #7  
#9 prophyla* or prevent* or premedicat* or pre-medicat*:ti,ab,kw  (Word variations have been searched) 
#10 #8 and #9  
#11 MeSH descriptor: [Antibiotic Prophylaxis] explode all trees 
#12 #10 or #11  
#13 #4 and #12  
#14 MeSH descriptor: [Endocarditis, Bacterial] explode all trees and with qualifier(s): [Prevention & control - PC] 
#15 endocarditis and prophyla*:ti  (Word variations have been searched) 
#16 #13 or #14 or #15  
 
 
WOK 
 
Set Results Save search history and/or create an alertOpen a saved search history 
1 29,469 TOPIC: (endocarditis) OR TOPIC: (((infect* or inflam*) NEAR/5 endocardium)) OR TOPIC: (ABE OR SABE) 
2 459,418 TS=(antibiotic* or anti-biotic* or antimicrobial* or anti-microbial* or antibacterial* or anti-bacterial* or anti-infective) OR  
TS=(penicillin or amoxicillin or ampicillin or cefazolin or ceftriaxone or cephalexin or clindamycin or azithromycin or clarithromycin or vancomycin) 
3 1,167,210 TOPIC: (prophyla* or prevent* or premedicat* or pre-medicat*) 
4 1,506 #3 AND #2 AND #1 
5 606 TITLE: (endocarditis AND prophyla*) 
6 1,785 #5 OR #4 
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Supplementary Table 1: Excluded studies 
 
First author Publication year PMID/PMCID Reason excluded 
Agha 2005 15951458 Outcome of interest not reported 
Aitken  1995 7599015 No control/placebo group 
Alexander 2013 Abstract No population incidence pre/post guideline reported 
Al-Karaawi 2001 11119466 Outcome of interest not reported 
Al-Omari 2014 24624933 Treatment of infective endocarditis study 
Aoki 1996 NA No abx prophylaxis intervention group 
Baddour 2013 NA Comment/editorial/review 
Bain 1985 NA Comment/editorial/review 
Baltch 1988 3365078 No control/placebo group 
Bates 2015 Abstract No population incidence pre/post guideline reported 
Bikdeli  2012 Abstract Dataset/analysis included in later publication 
Bolukbasi 2012 22157668 No abx prophylaxis intervention group 
Bor 2013 23527296 No population incidence pre/post guideline reported 
Bor 1984 6711576 Modelling study/extrapolated data 
Brennan 2007 17197406 Dataset/analysis included in later publication 
Bublak 2014 25608390 Comment/editorial/review 
Bunnell 2011 NA No control/placebo group 
Carretta 1988 3167905 Unobtainable 
Casas 1999 10231302 Unobtainable 
Cannon 1987 3610906 Outcome of interest not reported 
Cecchi 2009 18404005 No control/placebo group 
Chen 2015 26512586 Outcome of interest not reported 
Cherry 2007 17309589 Study of topical antibiotic/antiseptic 
Clark 1969 5192402 Patient population 
Connor 1967 5234633 Unobtainable 
Cosgrove 2011 Abstract No population incidence pre/post guideline reported 
Couturier 2000 NA Comment/editorial/review 
Crasta 2009 19426179 No abx prophylaxis intervention group 
Curran 1976 1075923 Unobtainable 
Daly 1997 9153833 No abx prophylaxis intervention group 
Daly 2001 11288795 No abx prophylaxis intervention group 
Dankert 1982 NA No abx prophylaxis intervention group 
Dankert  1985 NA Animal study 
Darhous 1993 9588119 Unobtainable 
Dayer 2010 Abstract Dataset/analysis included in later publication 
Dayer 2014 Abstract Dataset/analysis included in later publication 
Dayer 2011 Abstract Dataset/analysis included in later publication 
DeSimone 2015 26386808 No population incidence pre/post guideline reported 
De Aguir 2012 22522720 No abx prophylaxis intervention group 
De Leo 1974 4519445 No abx prophylaxis intervention group 
Delahaye 2011 Abstract Dataset/analysis included in later publication 
Dell'Atti 2013 Abstract Outcome of interest not reported 
Diz 2013 Abstract Group sizes not reported 
Doshi 2007 Abstract No population incidence pre/post guideline reported 
Durak 1982 6632128 Outcome of interest not reported 
Durak 1975 NA Comment/editorial/review 
Duval 2006 16705565 Modelling study/extrapolated data 
Edwards 2015 Abstract No population incidence pre/post guideline reported 
Ellervall 2010 20134479 Systematic review 
Erichsen 2016 27339641 No population incidence pre/post guideline reported 
Esposito 2013 18646101 Systematic review 
Feinstein 1961 13698654 Comment/editorial/review 
Francioli 1985 3925031 Animal study 
Friedlander 2010 20189771 Comment/editorial/review 
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Garlando 1988 3292185 Patient population 
Glenny 2013 241108511 Systematic review 
Goker 1992 1308784 Unobtainable 
Grattan 2013 26319967 No abx prophylaxis intervention group 
Grimard 1987 3680973 Unobtainable 
Grimard 1986 NA No abx prophylaxis intervention group 
Guntheroth 1984 6486031 Outcome of interest not reported 
Guze 1983 6418063 Animal study 
Hakata 2014 NA No abx prophylaxis intervention group 
Harris 1999 10604613 Patient population 
Hartzell 2005 15832100 No abx prophylaxis intervention group 
Harvey 1961 13712066 Outcome of interest not reported 
Hess 1977 NA Foreign language 
Hess 1981 Abstract No control/placebo group 
Hess 1983 6549771 No control/placebo group 
Hess 1983 6550789 No control/placebo group 
Ho 2015 NA No population incidence pre/post guideline reported 
Kaplan 1971 NA Comment/editorial/review 
Kaplan 1983 6889082 Comment/editorial/review 
Kaplan 1983 NA Unobtainable 
Kaneko 1995 8869455 No control/placebo group 
Katoh  1992 1300669 No control/placebo group 
Kernodle 1993 8494364 Animal study 
Kinane 2005 15966875 No abx prophylaxis intervention group 
Klug 2007 17724263 Patient population 
Kumana 1986 3099944 Outcome of interest not reported 
Lador 2012 41122 No control/placebo group 
Lee 2007 17761735 Outcome of interest not reported 
Lee 2009 NA Outcome of interest not reported 
Lockhart  2009 2770162 No abx prophylaxis intervention group 
Longman 1991 1990136 Outcome of interest not reported 
Lucas 2000 10769852 Outcome of interest not reported 
Oakley 1982 NA No control/placebo group 
Macgregor 1987 NA Unobtainable 
Magelli 1987 NA Unobtainable 
Maharaj 2012 3734757 No abx prophylaxis intervention group 
Martin 1964 14244278 Unobtainable 
Mazocchi 2007 17954332 No abx prophylaxis intervention group 
Messini 1999 10412852 No abx prophylaxis intervention group 
Monaco 2009 19531419 Outcome of interest not reported 
Mougeot 2015 25758845 Dataset/analysis included in later publication 
Murillo 1978 NA Outcome of interest not reported 
Murillo 1979 463947 Outcome of interest not reported 
Murphy 2006 16968327 No abx prophylaxis intervention group 
Murugiah 2013a Abstract No population incidence pre/post guideline reported 
Murugiah 2013b Abstract No population incidence pre/post guideline reported 
Niederau 1994 7988813 Patient population 
Nelson 1965 NA Patient population 
Niwa 2005 1768964 Outcome of interest not reported 
Oliver 2004 15106220 Systematic review 
Pant 2015b 26338002 Comment/editorial/review 
Pasquali 2011 Abstract No population incidence pre/post guideline reported 
Pasquali 2012 22607869 No population incidence pre/post guideline reported 
Pasquantonio 2012 23058035 Outcome of interest not reported 
Peterson 1976 1253389 No abx prophylaxis intervention group 
Pineiro 2010 20701619 Study of topical antibiotic/antiseptic 
Piper 2012 Abstract Outcome of interest not reported 
Rahn 1995 NA Unobtainable 
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Rechmann 1989 2639069 Study of topical antibiotic/antiseptic 
Rieder 1980 7423172 Patient population 
Roberts 1997 8960488 No abx prophylaxis intervention group 
Roberts 2002 12572738 No control/placebo group 
Roberts 2000 10689771 No abx prophylaxis intervention group 
Rogers 2008 18513601 No population incidence pre/post guideline reported 
Sasaki 1994 NA No control/placebo group 
Sasaki 1998 NA No control/placebo group 
Sasaki 2001 NA Foreign language 
Santinga 1976 1067349 Outcome of interest not reported 
Santinga 1984 NA No control/placebo group 
Sefton 1990 2196261 Duplicate data (Cannell et al) 
Schirger 1964 14146015 No control/placebo group 
Schlein 1991 2028936 No abx prophylaxis intervention group 
Schwartz 2007 17904722 Systematic review 
Shanson 1983 6130318 Outcome of interest not reported 
Shanson 1984 6334070 Outcome of interest not reported 
Sheenchen 1994 8310405 Patient population 
Smith 1989 2732123 Outcome of interest not reported 
Tempelhof 2012 NA Systematic review 
Thompson 1979 NA Outcome of interest not reported 
Thornhill 2011 21540258 Dataset/analysis included in later publication 
Thornhill 2015 25925595 Outcome of interest not reported 
Tozer 1966 4159601 Outcome of interest not reported 
Tuback 2002 NA Comment/editorial/review 
Tzuckert 1978 285049 Unobtainable 
Wong 2011 NA No population incidence pre/post guideline reported 
Yoshimura 1985 2939227 Unobtainable 
Yurtman 2010 NA Patient population 
Zhang 2013 23137266 No abx prophylaxis intervention group 
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Supplementary Table 2: Risk of bias summary – time trend studies 
 
 
 
Bates et al 
2016[1] 
Bikdeli et al  
2013[2] 
Dayer et al  
2015[3] 
DeSimone et al  
2015[4] 
Duval et al  
2012[5] 
Mackie et al  
2016[6] 
Pant et al  
2015[7] 
Salam et al  
2014[8] 
van den Brink et al 
2016[9] 
Definition of study group 
and IE diagnosis 
Clearly defined. 
Quote: ‘children 
≤18 years of age 
hospitalised with 
infective 
endocarditis – 
defined as having 
an ICD-9 
diagnosis code 
for “acute and 
subacute 
bacterial 
endocarditis”’ 
Clearly defined. 
Quote: 'All inpatient 
admissions of fee-
for-service 
beneficiaries age 
>65yrs from 1999 
to 2010'.  'Patients 
with a principal or 
secondary ICD-9-
CM discharge 
diagnosis of 
endocarditis were 
included' 
Clearly defined. 
Quote: 'We identified 
all patients with a 
primary discharge 
diagnosis of acute or 
subacute infectious 
endocarditis (ICD-10 
code 133.0) including 
those who died in 
hospital' 
Clearly defined. 
Quote: 'All Olmsted 
County residents 
aged >18yrs with 
definite or possible IE 
caused by VGS as 
defined by the 
modified Duke criteria 
between January 1, 
1999 and December 
31, 2013 were 
identified' 
Clearly defined. 
Quote: The 
modified von Reyn 
classification being 
the only available 
classification for all 
3 surveys was 
chosen to describe 
the changes over 
the 3 periods' 
Clearly defined. Quote: 
'All hospitalisations with 
'acute or subacute 
endocarditis (ICD-9 
421.0-421.9 or ICD-10 
133.0-133.9) in the 
main diagnosis filed 
were included' 
Clearly defined. 
Quote: 'We used the 
ICD clinical 
modification code to 
identify patients 
discharged with acute 
and subacute 
bacterial endocarditis 
between 2000 and 
2011' 
Not defined. Abstract 
only.  
Clearly defined. 
Quote: ‘This 
insurance database 
has a code uniquely 
for IE’ 
Characteristics of each 
group described 
Yes. Age, gender, 
presence of 
congenital heart 
disease and in 
hospital mortality. 
Yes. Age, gender, 
race, CV risk 
factors, past 
medical history  
No group 
demographics or 
characteristics 
provided   
Age- and sex-
adjusted incidence 
Yes: Age, sex, past 
medical history 
Yes: Age, sex, cardiac 
predisposing factors, 
other predisposing 
factors  
No group 
demographics or 
characteristics 
provided   
No group 
demographics or 
characteristics 
provided   
Yes. Age, gender, 
pre-existing valve 
disease, prosthetic 
valves, mortality, 
blood cultures, valve 
involved, organism 
Interval of sampling 6-monthly Yearly Monthly Yearly 1991, 1999 & 2008 Yearly  Yearly 4-yearly Yearly 
Data source Quote: ‘The 
Pediatric Health 
Information 
System Database 
was utilised’ 
Quote: 'Using the 
Centers for 
Medicare & 
Medicaid Services 
Medicare inpatient 
Standard Analytic 
Files'  
Quote: 'Data for the 
prescription of 
antibiotic prophylaxis 
were obtained from 
the NHS Business 
Services Authority'. 
'Incidence data for IE 
& associated mortality 
were obtained from 
national episode 
statistics’  
Quote: 'The 
Endocarditis Registry 
of the Division of 
Infectious Diseases at 
Mayo Clinic and the 
Rochester 
Epidemiology Project 
(REP) database were 
our primary resources 
for case 
ascertainment and 
data collection' 
Quote: 'Population-
based survey 
methods' 
Quote: 'The Canadian 
Institute for Health 
Information Discharge 
Abstract Database V 
data included from all 
Canadian provinces 
except Quebec and the 
Northern territories 
between April 1, 2002 
and March 31, 2013' 
Quote: The healthcare 
cost and utilisation 
project NIS database'  
Not defined Quote: ‘Data were 
extracted from the 
Dutch Healthcare 
Authority’ 
Is the group representative 
of the population of 
interest? 
Yes Yes Yes Yes Yes Yes Yes Unclear Yes 
Correlated change in 
incidence with change in 
antibiotic prophylaxis over 
time? 
No No  Yes No No No No No No 
Overall risk of bias High High High High High High High High High 
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Supplementary Table 3: Risk of bias summary – observational studies 
  
  
 
Horstkotte et al 1987[10] Imperiale et al 1990[11] Lacassin et al 1995[12] Strom et al 1998 Van der Meer et al 1992[13] 
Definition of cases Catchment area and time period 
not specified. Cases defined as 
'229 patients in whom 287 
diagnostic and therapeutic 
procedures were performed using a 
prophylactic antibiotic regime 
correctly administered. 
Catchment area and time period 
specified. Clearly defined inclusion and 
exclusion criteria. Presence of infective 
endocarditis determined using the 
modified Von Reyn criteria.  
Catchment area and time period specified. 
Clearly defined inclusion and exclusion criteria. 
Quote: 'Definite and probably IE was defined 
according to Von Reyn's criteria revised with 
the following modifications to include 
echocardiographic and macroscopic findings 
for definite and probably cases. Definite 
endocarditis was defined on macroscopy or 
microbiological findings on operation or 
necropsy; probably endocarditis was defined as 
(1) persistently positive blood cultures with 
underlying heart disease plus 
echocardiographic vegetation or with vascular 
phenomena plus echocardiographic vegetation 
or with vascular phenomena plus 
echocardiographic vegetation or (2) negative or 
intermittently positive blood cultures with fever, 
underlying heart disease, vascular phenomena, 
and echocardiographic vegetation'.  
Catchment area and time period 
specified. Inclusion and exclusion 
criteria clearly defined. Infective 
endocarditis not determined using 
diagnostic criteria. Quote: 'These 
experts used their own global clinical 
judgement to classify potential cases 
as definite, probably or possible cases'.  
 
Catchment area and time period 
specified. Clearly defined inclusion and 
exclusion criteria. Presence of infective 
endocarditis was determined by the 
Von Reyn criteria.  
Definition of controls  Catchment area and time period 
not specified. 'The second patient 
group consisted of 304 out of 1898 
patients questioned in our 
outpatient clinic, who gave reliable 
information that they had 
undergone one of the procedures 
we regard as requiring endocarditis 
prophylaxis, without having 
received any antibiotic regime'. 
Time period specified and catchment area 
specified and same as cases. Inclusion 
clearly defined. Exclusion criteria clearly 
defined and same as cases.   
Defined, but different population as cases. 
Quote: 'Controls were subjects without infective 
endocarditis who satisfied the same exclusion 
criteria as the cases. There were all recruited 
randomly from wards either during a 
consultation for echo or during hospitalisation 
in the same period of observations as cases'. 
'Each case was matched to one control as 
regards sex, age and group of underlying 
cardiac conditions'.  
Catchment area and time period not 
specified. Inclusion poorly defined. 
Exclusion criteria for controls not 
defined. Recruited using a modification 
of the Waksberg random-digit dialling 
method 
 
Catchment area specified, differing 
from cases. Time period not specified. 
Inclusion and exclusion criteria clearly 
described 
Characteristics of each 
group described  
No Yes: Age, gender, cardiac lesion, history 
or rheumatic fever, murmur duration, 
frequency of dental visits, dental clearing 
at zero time visit, use of diuretics, use of 
digitalis, penicillin allergy 
Yes: Age, sex, valve disease, duration of 
previous cardiac disease, known cardiac 
disease 
Only age 
 
Yes: Age, procedures, interval between 
procedure and onset of symptoms  
Groups recruited at 
common stage, in the 
same manner 
Not specified  
 
 
 
Cases and controls were recruited during 
the same time period and from the same 
catchment area. Both cases and controls 
were recruited in the same manner, in the 
form of a letter.  
Cases and controls were recruited during the 
same time period, but catchment area and 
manner of recruitment not specified  
Catchment area and time period for 
recruitment of controls not specified. 
Method of recruitment not specified.    
 
Cases and controls were recruited from 
different catchment areas. Time period 
of recruitment of controls not specified. 
Manner of recruitment differed between 
cases and controls: cases were 
selective consecutively and interviewed 
in person; controls were selected 
randomly, sent a letter and then a 
telephone call 
Sampling strategy Not specified  
 
 
 
Cases: preliminary selected by review of 
medical and dental records, and 
completion of telephone interview. 
Controls: all patients who underwent 
echocardiographic evaluation during the 
period covered by the study.  
Not specified Catchment area and time period for 
recruitment of controls not specified. 
Sampling strategy varied: controls were 
randomly recruited from the 
community; controls were recruited 
from all in patients with a putative 
diagnosis of endocarditis. 
 
Cases: Quote 'All patients who were 
consecutively admitted to hospital in 
the Netherlands and who were 
suspected of having bacterial 
endocarditis'. Comment: defined 
catchment area over a defined period 
of time. Controls: sampling strategy not 
specified.  
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Is the group 
representative of the 
population of interest 
In part, but also included 
procedures other than dental, such 
as urological and gynaecological 
Yes Yes – only dental subgroup analysed Yes Overall yes, although < 10% of 
procedures were non-dental 
Duration of follow-up No follow-up No-follow up No follow-up  No follow-up No follow-up 
Outcome assessment: 
Objective or 
independently 
adjudicated? 
Outcome: Prosthetic valve 
endocarditis. Method or criteria for 
diagnosis of endocarditis is not 
described. 
Telephone interview, use of a standard 
structured questionnaire not described. 
Specific purpose of research was not 
revealed to the interview subjects. Use of 
independent adjudicator not described.  
Cases and controls were interviewed using the 
same questionnaire. Use of an independent 
adjudicator, or blinding of the participants to the 
study purpose is not described 
Structured telephone interview where 
cases and controls completed the 
same structured questionnaire.  Use of 
an independent adjudicator or blinding 
of the participants to the study purpose 
is not described 
 
Telephone interview where cases and 
controls completed the same structured 
questionnaire.  Use of an independent 
adjudicator, or blinding of the 
participants to the study purpose is not 
described 
Overall risk of bias High High High High High 
 
Page 36 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Table 4 – Risk of bias summary – bacteraemia trials 
 
 
 
Supplementary Table 4. Risk of bias assessment for trials of antibiotic prophylaxis. 
All trials were assessed using the Cochrane risk of bias tool. Symbols:  low risk of 
bias,  high risk of bias,  unclear risk of bias 
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Supplementary Table 5: Data extraction – bacteraemia trials 
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I
n
d
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Adults (aged 35-45 
years) 
Periodontal 
flap 
procedure 
(under LA) 
Amoxicillin 
500mg PO, 2h 
pre-procedure NA NA NA 
Each 
patient 
served as 
own control 
- separate 
quadrants 
Blood cultures 
taken during 
procedure 30 NA NA NA 30 
4/30 
(13.3%) NA NA NA 
14/30 
(46.6%) Not reported 
Control group: 
4/30 (13.3%). 
Abx group: 
1/30 (3.3%) 
B
a
l
t
c
h
,
 
1
9
8
2
[
1
5
]
 
7
1
4
8
6
5
2
 
T
N
R
 
P
a
p
e
r
 
U
S
A
 
Adults (age not 
specified): 28 with 
known cardiac 
abnormality 
(prophylaxis group); 
28 without cardiac 
abnormality (control 
group) 
Dental 
cleaning 
Penicillin G 
2million units 
IV, over 30-
40mins pre-
procedure, 
continued for 
72h NA NA NA 
Control 
group 
Blood cultures 
taken pre- and  
5 and 30 mins 
post-
procedure 28 NA NA NA 28 
3/28 
(10.7%) at 
5 
minutes; 
4/26 
(15.4%) at 
30 
minutes NA NA NA 
17/28 
(60.7%) at 
5 
minutes; 
7/28 (25%) 
at 30 
minutes Not reported 
Control group: 
4/28 (14.3%) at 
5 mins, 1/28 
(3.6%) at 30 
mins. Abx 
group: 1/28 
(3.6%) at 5 
mins, 1/26 
(3.9%) at 30 
mins 
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2
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P
a
p
e
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U
S
A
 
Adults (range 19 – 
83) undergoing 
dental extraction, 
33/128 with known 
valvular heart 
disease 
Dental 
extraction 
(LA) 
Aqueous 
penicillin G 2 
million units 
IV 30 minutes 
before the 
procedure and 
every 4 hours 
for 72 hours 
thereafter  
Penicillin V 
orally 0.5-
1g 30-45 
minutes 
prior to the 
procedure NA NA 
Control 
group (29 
under local 
anaesthesia 
used to 
match 
antibiotic 
groups) 
Blood cultures 
pre- and 5 and 
30 mins post-
procedure 33 36 NA NA 29 
11/32 
(34.4%) at 
5 
minutes; 
4/33 
(12.1%) at 
30 
minutes 
17/36 
(47.2%) at 
5 
minutes; 
5/36 
(13.9%) at 
30 
minutes  NA NA 
17/29 
(58.6%) at 
5 
minutes; 
8/29 
(26.7%) at 
30 
minutes 
Number of 
isolates per 
positive blood 
culture at 5 
minutes: IV 
penicillin 1.6, 
PO penicillin 
2.5, control 
group 4.1 
Proportion 
with 
streptococcal 
bacteraemia at 
5 mins: IV 
penicillin 1/32 
(3.1%), PO 
penicillin 1/36 
(2.8%), control 
group 17/30 
(56.7%) 
C
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l
l
,
 
1
9
9
1
[
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7
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R
C
T
 
P
a
p
e
r
 
U
K
 
Adults (aged 18-65 
years) 
Dental 
extraction 
(anaestheti
c not 
specified) 
Erythromycin 
1.5g PO, 1-
1.5h pre-
procedure 
Josamycin 
base 1.5g, 
1-1.5h pre-
procedure NA NA 
Placebo 
group 
Blood cultures 
taken, timing 
not specified 20 20 NA NA 20 
12/20 
(60%) 
14/20 
(70%) NA NA 
13/20 
(65%) Not reported Not reported 
C
o
u
l
t
e
r
,
 
1
9
9
0
[
1
8
]
 
 
T
N
R
 
P
a
p
e
r
 
U
K
 
Children (aged 2-13 
years) 26 with 
known cardiac 
abnormality 
(prophylaxis group); 
32 with no cardiac 
abnormality (control 
group) 
Dental 
extraction 
(under GA) 
Penicillin IM 
(dose and 
timing not 
specified) 
Amoxicillin 
PO (dose 
and timing 
not 
specified) 
Amoxicillin 
IV (dose 
and timing 
not 
specified) 
Erythromyc
in IV (dose 
and timing 
not 
specified) 
Control 
group 
Blood cultures 
taken 1-2 
minutes post-
extraction 8 8 6 4 32 
Overall 
9/26 (35%) NA NA NA 
20/32 
(63%) Not reported 
Number of 
patients with 
streptococcal 
bacteraemia in 
each group: 
3/26 with AP; 
12/32 without 
AP 
D
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]
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P
a
p
e
r
 
S
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i
n
 
Adults (aged >/=18 
years) with learning 
difficulties 
Dental 
extraction 
(under GA) 
Amoxicillin 2g 
PO, 1-2h pre-
procedure 
Clindamyci
n 600mg 
PO, 1-2h 
pre-
procedure 
Moxifloxaci
n 400mg 
PO, 1-2h 
pre-
procedure NA 
Control 
group 
Blood cultures 
taken at 0s, 
30s, 15min 
and 1h post-
extraction 56 202 58 NA 53 
46.4% 
(n=26) at 
30s, 
10.7% at 
15mins, 
3.7% at 1h 
85.1% 
(n=46) at 
30s, 
70.4% at 
15mins, 
22.2% at 
1h 
56.9% at 
30s 
(n=33), 
24.1% at 
15mins, 
7.1% at 1h NA 
96.2% 
(n=51) at 
30s,  
64.2% at 
15mins, 
20% at 1h Not reported 
% of cultures 
+ve for 
streptococci: 
Control group: 
63.1%. Amox 
group: 44.4%. 
Clindamycin 
group: 58.5%. 
Moxifloxacin: 
67.7% 
D
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Adults (aged 18-29 
years) 
Dental 
extraction 
(under LA) 
Amoxicillin 2g 
PO, 1h pre-
procedure 
Chlorhexidi
ne rinse. 1h 
pre-
procedure NA NA 
Placebo 
group 
Blood cultures 
taken before 
and 1.5 
minutes after 
2nd 
extraction, 1.5 
mins after 4th 
extraction, 
then at 10 
mins after 4th 
extraction 10 10 NA NA 10 4/10 (40%) 6/10 (60%) NA NA 5/10 (50%) 
Magnitude of 
bacteraemia 
(SD): placebo 
group 3.61+/-
7.09 CFU/ml; 
amoxicillin 
0.63+/-1.33 
cfu/ml; 
chlorhex 
2.76+/-4.28 
cfu/ml 
Number of 
alpha/hemolyti
c/VGS 
isolates: 
placebo 5, 
chlorhexidine 
2, amoxicillin 1 
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Adults (aged 23-74 
years) 
Dental 
extraction 
(under LA) 
Penicillin V 1g 
PO x2, 1h pre-
procedure 
Amoxicillin 
750mg PO 
x4, 1h pre-
procedure NA NA 
Placebo 
group 
Blood cultures 
taken during 
procedure and 
10 minutes 
post-
procedure 20 20 NA NA 20 
Overall 
90% 
(n=18). 
90% 
during 
procedure
, 70% at 
10 mins 
Overall 
85% 
(n=17). 
85% 
during 
procedure
, 60% at 
10 mins NA NA 
Overall 
95% 
(n=19). 
90% 
during 
surgery, 
80% at 10 
mins 
Median cfu per 
ml reported: 
During 
procedure Pen 
V 0.66, Amox 
1.08, Placebo 
0.84; 10mins 
post-
procedure: 
Pen V 0.36, 
Amox 0.24, 
Placebo 0.36 
VGS isolated 
during 
procedure: 
Pen V 70%, 
Amox 55%, 
Placebo 70%; 
VGS 10mins 
post-
procedure: 
Pen V 25%, 
Amox 30%, 
Placebo 40% 
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Adults (aged 21-66 
years) 
Dental 
extraction 
(anaestheti
c not 
specified) 
Cefaclor 1g 
PO, 1h pre-
procedure NA NA NA 
Placebo 
group 
Blood cultures 
taken pre-, 
during and 10 
minutes post-
procedure 19 NA NA NA 20 
79% 
(n=15) 
during 
procedure
, 53% at 
10 mins NA NA NA 
85% 
(n=17) 
during, 
47% at 10 
mins 
See 
bacteraemia at 
10 minutes 
outcome 
Control group: 
50% during 
procedure, 
30% at 10 mins 
post-
procedure. 
Cefaclor 
group: 79% 
during 
procedure, 
26% at 10 mins 
post-
procedure  
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C
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Adults (aged 16-60 
years) 
Dental 
extraction 
(under LA) 
Penicillin V 2g 
PO, 1h pre-
procedure 
Metronidaz
ole 2g PO, 
1h pre 
procedure NA NA 
Placebo 
group 
Blood cultures 
taken 1 minute 
post-
extraction 25 25 NA NA 25 20% 52% NA NA 84% 
Pour plates' 
were all 
negative - 
bacteraemias< 
1 
microorganis
m per ml of 
blood 
Reported - 
need to check 
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Not specified 
Dental 
extraction 
(under LA) 
Erythromycin 
PO, varying 
dose from 
250mg-
1000mg at 
varying time 
90-240mins 
pre-procedure 
Tetracyclin
e 275mg IV, 
3 mins pre-
procedure NA NA 
Control 
group 
Blood cultures 
taken, timing 
not specified 42 100 NA NA 100 
16/42 
(38%) 3/100 (3%) NA NA 
64/100 
(64%)  
Control group: 
44 (44%); 
Pyrrolidino 
group: 2 (2%) 
L
i
m
e
r
e
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P
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s
s
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Adults (aged >=18 
years) 
Dental 
extraction 
(under GA) 
Amoxicillin/cla
vulanate 
1000/200mg 
IV, after 
induction 
Amoxicillin 
2g PO, 1-2h 
before 
induction 
Clindamyci
n 600mg 
PO, 1-2h 
before 
induction 
Azithromyci
n 500mg 
PO, 1-2h 
before 
induction 
Control 
group - 
unmedicate
d 
Blood cultures 
pre-
procedure,  
30s post-
extraction, 
and 15 and 60 
mins post-
procedure 52 50 52 57 55 0/52 (0%) 
25/50 
(50%) 
45/52 
(87%) 
46/57 
(81%) 
53/55 
(96%) 
Results also 
reported at 15 
mins and 1h 
Percentage of 
positive 
cultures that 
were VGS: 
Control-50%; 
Amoxicillin/Cla
vulanate-0%; 
Amoxicillin-
31%; 
Clindamycin 
56%; 
Azithromycin 
53% 
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P
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p
e
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U
S
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Children (mean age 
3.5 years) 
Dental 
extraction 
(under GA) 
Amoxicillin 
50mg/kg PO, 
1h pre-
procedure NA NA NA 
Placebo 
group 
Blood cultures 
taken pre-, 
during and 15, 
30 and 45 
mins post-
procedure 49 NA NA NA 51 
16/49 
(33%) NA NA NA 
43/51 
(84%) 
Duration 
reported:  at 
15 minutes 
12% vs 1%, at 
30 mins 9% vs 
0%, at 45 mins 
5% vs 0% - all 
prophylaxis vs 
placebo 
Numbers of 
positive 
cultures for 
VGS. Control 
group: 45% 
(n=57). 
Amoxicillin 
group: 33% 
(n=8) 
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k
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2
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Not specified, (mean 
age 40 years) 
Dental 
extraction 
(under LA) 
Amoxicillin 
(dose, route 
and timing not 
specified) 
Tooth 
brushing NA NA 
Placebo 
group 
Blood cultures 
taken pre-, 
during, and 
20, 40 and 60 
mins post-
procedure 90 89 NA NA 89 56% 32% NA NA 80% 
Duration is 
reported. All 
analysed 
samples were 
below the 
detection 
threshold of 
104 CFU per 
millilitre of 
blood 
Numbers of 
positive 
cultures for 
VGS. Control 
group: 106/151 
(70%). 
Amoxicillin 
group: 23/47 
(49%) 
M
a
h
a
r
a
j
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2
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2
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2
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A
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Adults (aged 18-66 
years), without 
underlying valve 
disease or 
prosthetic valve 
Dental 
extraction 
(anaestheti
c not 
specified) 
Amoxicillin 3g 
PO, 1h pre-
procedure 
Clindamyci
n 600mg 
PO, 1h pre-
procedure 
Chlorhexidi
ne rinse, 1h 
pre-
procedure NA 
Control 
group 
Blood cultures 
taken, timing 
not specified 40 40 40 NA 40 
3/40 
(7.5%) 8/40 (20%) 
16/40 
(40%) NA 14 (35%) Not reported 
Number of 
patients with 
positive VGS 
cultures: 
control group 
5; 
chlorhexidine 
5; amoxicillin 
0; clindamycin 
0 
M
a
s
k
e
l
l
,
 
1
9
8
6
[
2
9
]
 
2
9
4
1
4
0
4
 
T
N
R
 
P
a
p
e
r
 
U
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Not specified 
Dental 
extraction 
(anaestheti
c not 
specified) 
Teicoplanin 
200mg IM, 1h 
pre-procedure 
Amoxicillin 
3g PO, 1h 
pre-
procedure NA NA 
Control 
group 
Blood cultures 
taken during 
procedure 10 10 NA NA 10 6/10 (60%) 4/10 (40%) NA NA 
10 /10 
(100%) NA 
Control group 
9/10 (90% of 
patients had 
oral 
streptococci 
isolated; 5/10 
in teicoplanin 
group; 3/10 in 
amoxicillin 
group 
R
o
b
e
r
t
s
,
 
1
9
8
7
[
3
0
]
 
N
A
 
R
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d
o
m
i
s
e
d
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r
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P
a
p
e
r
 
U
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Children < 16 years 
Dental 
extraction 
Amoxicillin 
50mg/kg PO, 
2h pre-
procedure NA NA NA 
Control 
group 
Blood cultures 
pre procedure, 
post 
intubation and 
2 minutes 
post 
extraction 47 NA NA NA 47 
1/47 
(2.13%) NA NA NA 
18/47 
(38.3%) NA 
Control group 
– 14/47 
patients 
positive 
cultures for 
strep (VGS, 
non-
haemolytic or 
anaerobic 
strep) 
Amoxicillin 
group – 0/47 
positive 
culture due to 
strep 
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Abbreviations: LA – local anaesthetic, GA – general anaesthetic, IM intramuscular, IV intravenous, NA – not applicable, PO per oral, RCT – randomized controlled trial, TNR – trial, non-randomised  
*only viridans streptococcal bacteraemia reported 
 
 
 
S
h
a
n
s
o
n
,
 
1
9
7
8
[
3
1
]
 
9
9
4
2
3
 
R
C
T
 
P
a
p
e
r
 
U
K
 
Adults (age not 
specified) 
Dental 
extraction 
(anaestheti
c not 
specified) 
Penicillin V 2g 
PO, 1h pre-
procedure 
Amoxicillin 
2g PO, 1h 
pre-
procedure NA NA 
Control 
group - 
unmedicate
d 
Blood cultures 
taken 2 mins 
post-
extraction 40 40 NA NA 40 5/40 (12%) 2/40 (5%) NA NA 
16/40 
(40%)   
S
h
a
n
s
o
n
,
 
1
9
8
5
[
3
2
]
 
3
8
8
2
6
5
7
 
T
N
R
 
P
a
p
e
r
 
U
K
 
Adults (aged 18-71) 
Dental 
extraction 
(LA) 
Erythromycin 
stearate PO, 
1.5g given 1h 
pre-procedure NA NA NA 
Placebo 
group 
Blood cultures 
1-2 minutes 
following 
extraction 40 NA NA NA 42 
6/40 
(15%)* NA NA NA 
18/42 
(43%)* 
Serial 
dilutions 
reported 
See primary 
outcome for 
this study 
(only 
streptococcal 
bacteraemia 
reported) 
S
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a
n
s
o
n
,
 
1
9
8
7
[
3
3
]
 
2
9
5
7
3
4
8
 
R
C
T
 
P
a
p
e
r
 
U
K
 
Adults (aged 18-60 
years), without 
underlying valve 
disease or 
prosthetic valve 
Dental 
extraction 
(under GA) 
Teicoplanin 
400mg IV, 5-
10mins before 
extraction 
Amoxicillin 
1g IM, 20-
30mins 
before GA  NA  
Control 
group - 
unmedicate
d 
Blood cultures 
and antibiotic 
assay 
(treatment 
arms only) 
1.5-2mins 
post-
extraction. 
Antibiotic 
assay 
(treatment 
arms only) at 
4h 40 40 NA NA 40 2.50% 25% NA NA 32.50% Not reported 
VGS 
incidence. 
Control group: 
13/40. 
Teicoplanin 
group: 1/40 
V
e
r
g
i
s
,
 
2
0
0
1
[
3
4
]
 
1
1
1
7
4
5
9
2
 
R
C
T
 
P
a
p
e
r
 
U
S
A
 
Adults (aged 21-79 
years), without 
underlying valve 
disease or 
prosthetic valve 
Dental 
extraction 
(anaestheti
c not 
specified) 
2 x 60ml 
mouthwash 
applications 
containing 3g 
amoxicillin 
suspension 
per 
application, 
retained for 1-
2 mins each (2 
hours and 1 
hour before 
extraction) 
3g 
amoxicillin 
PO (1 hour 
before 
extraction) NA NA 
Control 
group - 
unmedicate
d 
Blood cultures 
taken post-
extraction (for 
1 extraction, 
after 
extraction; for 
2 extractions, 
after 2nd tooth 
extracted; for 
3 or more 
extractions, 
after 3rd or 
4th tooth 
extracted) 10 10 NA NA 9 6/10 (60%) 1/10 (10%) NA NA 8/9 (89%)     
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participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
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INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
7 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
NA 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
8 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
8 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Suppl 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
8 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8-9 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
8-9 
 
Page 46 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
PRISMA 2009 Checklist 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
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reporting within studies).  
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Suppl 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Suppl 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
14, 15, 
Figures 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figures 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Suppl 
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DISCUSSION   
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